NASDAQ$CRDF
Cardiff Oncology Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced second quarter 2021 results and provided business updates, highlighting clinical program advancements and financial performance.
Cardiff Oncology reported its second quarter 2021 results, highlighting advancements in its clinical programs, particularly in KRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company's leadership was strengthened with new appointments, and the financial results indicated a strong cash position of approximately $140 million.
- Lead clinical program in KRAS-mutated metastatic colorectal cancer continues to show robust response and progression-free survival.
- First patient dosed in Phase 2 study for metastatic pancreatic ductal adenocarcinoma.
- Appointed new CMO and CFO, and added two new board members with expertise in drug development and financial strategy.
- Company included as a member of FTSE Russell Indexes.
Headline financials
Revenue & EPS history
Cardiff Oncology · Revenue · Quarterly
$68K
Revenue by segment
Cardiff Oncology · $68K total across 1 segment · Q2 2021
- Royalties$68K—100.0%
Forward guidance
Cardiff Oncology anticipates continued progress in its clinical trials and efforts to expand onvansertib's pipeline of indications. The company expects a steady cadence of catalysts over the coming months, driven by its strong cash position and recent progress in clinical and preclinical programs.
Tailwinds
- Advancements in KRAS-focused programs for metastatic pancreatic ductal adenocarcinoma (mPDAC).
- Promising data from the lead KRAS-mutated metastatic colorectal cancer program.
- Expectations for continued progress in castrate-resistant prostate cancer trial.
- Advancements in efforts to expand onvansertib’s pipeline of indications.
- Strong cash position to support ongoing and future clinical trials.
Headwinds
- Clinical trials involve a lengthy and expensive process with an uncertain outcome.
- Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
- Risks related to business interruptions, including the outbreak of COVID-19 coronavirus.
- Uncertainties of government or third party payer reimbursement.
- Dependence on key personnel.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+2.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+3.0%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+118.2%
Q4 2010
Best reaction
-21.2%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +3.6% | — | |
| Q4 2025 | +12.9% | +14.1% | -8.8% | |
| Q3 2025 | -3.1% | -0.4% | -6.2% | |
| Q2 2025 | -1.3% | -24.2% | -36.6% | |
| Q1 2025 | +4.0% | +2.5% | +37.4% | |
| Q4 2024 | +4.4% | +5.2% | -19.0% | |
| Q3 2024 | -19.2% | -17.6% | -39.4% | |
| Q2 2024 | +11.2% | +5.1% | -1.4% | |
| Q1 2024 | -16.8% | -21.7% | -24.8% | |
| Q4 2023 | +59.9% | +100.5% | +193.4% | |
| Q3 2023 | +5.7% | +3.8% | +20.0% | |
| Q2 2023 | -5.0% | -8.3% | -15.6% | |
| Q1 2023 | +1.1% | -4.8% | -12.4% | |
| Q4 2022 | +2.3% | +7.6% | -4.1% | |
| Q3 2022 | -4.7% | -10.7% | +5.4% | |
| Q2 2022 | +15.0% | +30.0% | +27.7% | |
| Q1 2022 | -7.7% | -11.9% | -0.7% | |
| Q4 2021 | +7.1% | +0.4% | -5.6% | |
| Q3 2021 | -5.1% | -3.6% | -14.1% | |
| Q2 2021 | +15.0% | +19.4% | +51.3% | |
| Q1 2021 | -5.5% | -13.1% | -24.5% | |
| Q4 2020 | +0.6% | +8.0% | -3.1% | |
| Q3 2020 | +10.6% | +5.8% | +26.6% | |
| Q2 2020 | -14.6% | -10.2% | -3.4% | |
| Q1 2020 | +0.8% | +6.7% | +167.5% | |
| Q4 2019 | -2.8% | +12.8% | -24.1% | |
| Q3 2019 | +1.8% | +2.4% | -20.8% | |
| Q2 2019 | -4.1% | -10.0% | +10.6% | |
| Q1 2019 | -8.1% | -11.2% | -11.2% | |
| Q4 2018 | +25.2% | +47.0% | +18.2% | |
| Q3 2018 | +6.7% | +4.0% | -6.7% | |
| Q2 2018 | -1.2% | -1.2% | +0.0% | |
| Q1 2018 | +0.0% | -3.6% | -47.3% | |
| Q4 2017 | -6.2% | -3.1% | +6.2% | |
| Q3 2017 | -1.5% | -4.4% | -26.5% | |
| Q2 2017 | -7.1% | +1.2% | -13.1% | |
| Q1 2017 | -5.0% | -1.2% | +1.3% | |
| Q4 2016 | -21.2% | -28.5% | -37.0% | |
| Q3 2016 | -5.6% | -15.5% | -29.6% | |
| Q2 2016 | -6.6% | -0.4% | -11.0% | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -18.7% | — | — | |
| Q3 2015 | +11.7% | — | — | |
| Q2 2015 | -15.0% | — | — | |
| Q1 2015 | +9.6% | — | — | |
| Q4 2014 | +0.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q4 2013 | +7.9% | — | — | |
| Q3 2013 | +12.2% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q4 2012 | -2.4% | — | — | |
| Q1 2013 | -2.4% | — | — | |
| Q3 2012 | +2.3% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | +8.8% | — | — | |
| Q4 2011 | -3.9% | — | — | |
| Q3 2011 | -17.1% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +118.2% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +13.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro